Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adenosine receptor agonists: from basic medicinal chemistry to clinical development.

Luo Yan1, Joachim C Burbiel, Astrid Maass

  • 1University of Bonn, Pharmaceutical Institute Poppelsdorf, Kreuzbergweg 26, D-53115 Bonn, Germany.

Expert Opinion on Emerging Drugs
|December 10, 2003
PubMed
Summary

Adenosine receptors are key targets for treating various diseases. Developing selective adenosine receptor agonists faces challenges like side effects and poor brain penetration, necessitating novel therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychedelics and Entactogens.

Journal of medicinal chemistry·2026
Same author

Neuroglial P2Y<sub>1</sub> receptor signalling differentially contributes to inflammatory neurodegeneration.

Journal of neuroinflammation·2026
Same author

Development of Novel Lysosome-Targeting Chimera by Non-covalent-Type Fc-IGF2 Complex (Fc-LYTAC) for Target Membrane Protein Degradation.

Chemical & pharmaceutical bulletin·2026
Same author

Inhibitors of Ectonucleotidase CD39 for Immunotherapy of Cancer and Infections─Recent Developments and Future Perspectives.

Journal of medicinal chemistry·2026
Same author

Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer.

Journal of medicinal chemistry·2026
Same author

Mechanism of GPR84 allosteric modulation at a helix 8-proximate site.

bioRxiv : the preprint server for biology·2026

Area of Science:

  • Pharmacology
  • Neuroscience
  • Cardiovascular Medicine

Background:

  • Adenosine is a vital nucleoside activating four G protein-coupled receptors (A1, A2A, A2B, A3) involved in numerous physiological and pathological processes.
  • Adenosine receptors are widely distributed across cells, but their subtype densities vary significantly, influencing therapeutic potential.
  • Adenosine itself has therapeutic applications, including treating arrhythmias and as a vasodilator in cardiac imaging.

Purpose of the Study:

  • To review the development and clinical applications of selective adenosine receptor agonists.
  • To identify challenges and limitations associated with current adenosine receptor-targeted therapies.
  • To explore alternative strategies for optimizing adenosine receptor-based treatments.

Main Methods:

Related Experiment Videos

  • Review of scientific literature on adenosine receptor pharmacology and therapeutics.
  • Analysis of clinical trial data for adenosine receptor agonists.
  • Examination of challenges including side effects, brain penetration, and compound half-life.

Main Results:

  • Selective agonists for A1, A2A, and A3 adenosine receptors have been developed, with several in clinical trials for cardiovascular diseases, pain, cancer, and inflammatory conditions.
  • Clinical evaluations have been halted for some agonists due to significant side effects, limited brain penetration, short half-lives, or lack of efficacy.
  • Receptor desensitization and low target tissue density may contribute to treatment failures.

Conclusions:

  • Despite therapeutic promise, adenosine receptor agonist development faces hurdles requiring innovative approaches.
  • Partial agonists, adenosine metabolism inhibitors, or allosteric activators may offer improved safety and efficacy profiles.
  • Further research into optimizing adenosine receptor modulation is crucial for advancing treatments for diverse conditions.